ABC | Volume 111, Nº3, Setembro 2018

Diretrizes Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda Arq Bras Cardiol. 2018; 111(3):436-539 failure in the elderly: the Cardiovascular Health Study and the Health, Ageing and Body Composition Study. Heart. 2011;97(16):1304-11. 343. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, andmanagementofhighbloodpressure inadults:areportoftheAmerican College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-248. Erratum in: J Am Coll Cardiol. 2018;71(19):2275-9. 344. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-16. 345. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels- updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34(4):613-22. 346. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a 
systematic review and meta-analysis. Lancet. 2016;387(10022):957-67. 347. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review andmeta-analysis. Lancet. 2016;387(10017):435-43. 348. Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine onmorbidity andmortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335(15):1107-14. 349. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000;283(15):1967-75. Erratum in: JAMA. 2002;288(23):2976. 350. Dorszewski A, Göhmann E, Dorszewski B, Werner GS, Kreuzer H, Figulla HR. Vasodilation by urapidil in the treatment of chronic congestive heart failure in additionto angiotensin-converting enzyme inhibitors is not beneficial: results of aplacebo-controlled, double-blind study. J Card Fail. 1997;3(2):91-6. 351. Bayliss J, Norell MS, Canepa-Anson R, Reid C, Poole-Wilson P, Sutton G. Clinicalimportance of the renin-angiotensin system in chronic heart failure: double blindcomparison of captopril and prazosin. Br Med J (Clin Res Ed). 1985;290(6485):1861-5. 352. Lee TT, Chen J, Cohen DJ, Tsao L. The association between blood pressure andmortality inpatientswithheartfailure.AmHeartJ.2006;151(1):76-83. 353. Anand IS, Rector TS, Kuskowski M, Thomas S, Holwerda NJ, Cohn JN. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial. Circ Heart Fail. 2008;1(1):34-42. 354. Debonnaire P, Al Amri I, Leong DP, Joyce E, Katsanos S, Kamperidis V, et al. Leaflet remodelling in functional mitral valve regurgitation: characteristics, determinants, and relation to regurgitation severity. Eur Heart J Cardiovasc Imaging. 2015;16(3):290-9. 355. Bursi F, Barbieri A, Grigioni F, Reggianini L, Zanasi V, Leuzzi C, et al. Prognostic implications of functional mitral regurgitation according to the severity of the underlying chronic heart failure: a long-termoutcome study. Eur J Heart Fail. 2010;12(4):382-8. 356. Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM. Impact of mitral valve annuloplasty onmortality risk in patients withmitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol. 2005;45(8):381-7. 357. Mihaljevic T, Lam BK, Rajeswaran J, Takagaki M, Lauer MS, Gillinov AM, et al. Impact of mitral valve annuloplasty combinedwithrevascularization in patients with functional ischemicmitral regurgitation. J AmColl Cardiol 2007;49(22):2191-201. 358. Seneviratne B, MooreGA,West PD. Effect of captopril on functional mitral regurgitation in dilated heart failure: a randomised double blind placebo controlled trial. Br Heart J. 1994;72(1):63-8. 359. Capomolla S, Febo O, Gnemmi M, Riccardi G, Opasich C, Caporotondi A, et al. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. Am Heart J. 2000;139(4):596-608. 360. Madaric J, Vanderheyden M, Van Laethem C, Verhamme K, Feys A, Goethals M, et al. Early and late effects of cardiac resynchronization therapy on exercise-induced mitral regurgitation: relationship with left ventriculardyssynchrony,remodellingandcardiopulmonaryperformance. Eur Heart J. 2007;28(17):2134-41. 361. Wang L, Li B, Liu C, Rong T, Yu Y, Gu C. Short- and medium-term effects of combined mitral valve surgery and coronary artery bypass grafting versus coronary artery bypass grafting alone for patients with moderate ischemicmitral regurgitation: ameta-analysis. J Cardiothorac Vasc Anesth. 2016;30(6):1578-86. 362. Mauri L, Foster E, Glower DD, Apruzzese P, Massaro JM, Herrmann HC, et al; EVEREST II Investigators. 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. J Am Coll Cardiol. 2013;62(4):317-28. 363. Vemulapalli S, Lippmann SJ, Krucoff M, Hernandez AF, Curtis LH, Foster E, et al. Cardiovascular events and hospital resource utilization pre- and post-transcatheter mitral valve repair in high-surgical risk patients. Am Heart J. 2017 Jul;189:146-57. 364. Adamo M, Barbanti M, Curello S, Fiorina C, Chiari E, Chizzola G, et al. Effectiveness of MitraClip therapy in patients with refractory heart failure. J Interv Cardiol. 2015;28(1):61-8. 365. Maisano F, Franzen O, Baldus S, Schafer U, Hausleiter J, Butter C, et al. Percutaneous mitral valve interventions in the real world: early and 1-yearresults from the ACCESS-EU, a prospective, multicenter, nonrandomized postapprovalstudy of the MitraClip therapy in Europe. J Am Coll Cardiol. 2013;62(12):1052-61. 366. Geis NA, Puls M, Lubos E, Zuern CS, Franke J, Schueler R, et al. Safety and efficacy of MitraClip™ therapy in patients with severely impaired left ventricular ejection fraction: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail. 2018;20(3):598-608. 367. Kelly TA, Rothbart RM, Cooper CM, Kaiser DL, Smucker ML, Gibson RS. Comparison of outcome of asymptomatic to symptomatic patients older than 20 years of age with valvular aortic stenosis. Am J Cardiol. 1988;61(1):123-30. 368. Varadarajan P, Kapoor N, Bansal RC, Pai RG. Clinical profile and natural historyof 453 nonsurgically managed patients with severe aortic stenosis. Ann Thorac Surg. 2006;82(6):2111-5. 369. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgicalaortic-valve replacement in high-risk patients. N Engl J Med 2011;364(23):2187-98. 370. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363(1):1597-607. 371. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al; U.S. CoreValve Clinical Investigators. Transcatheter aortic- valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370(19):1790-8. 372. Deeb GM, Reardon MJ, Chetcuti S, Patel HJ, Grossman PM, Yakubov SJ, et al; CoreValve US Clinical Investigators. 3-year outcomes inhigh-risk patientswhounderwentsurgicalortranscatheteraorticvalvereplacement. J Am Coll Cardiol. 2016;67(22):2565-74. 373. Clavel MA, Magne J, Pibarot P. Low-gradient aortic stenosis. Eur Heart J. 2016;37(34):2645-57. 527